MOTS-C 20mg Review

MOTS-c (Mitochondrial Open Reading Frame of the twelve S rRNA type-c) is a 16-amino-acid peptide encoded entirely within the mitochondrial genome, a biochemical fact that distinguishes it from virtually every other research peptide currently under investigation. Discovered in 2015 by Lee and colleagues at the University of Southern California, it has generated sustained interest across metabolic biology, geroscience, and exercise physiology because it appears to act as an endogenous signal linking mitochondrial stress to nuclear transcriptional programs. 1

Unlike peptides derived from precursor proteins in the nuclear genome, MOTS-c arises from a short open reading frame (ORF) embedded in the 12S rRNA gene of the human mitochondrial genome. This positional origin gives it unusual cell-biology properties: mitochondrial copy number, oxidative stress, and metabolic demand all modulate its production, making it a sensor-effector molecule rather than a conventional hormone. 2

The 20 mg vial format reviewed here represents a research-scale quantity appropriate for multi-cohort animal studies or comprehensive in-vitro dose-response experiments. This review synthesizes the current peer-reviewed literature, examines the available pharmacokinetic data, and evaluates what researchers should look for in a quality-controlled supply of this peptide.

Editor's Verdict

MOTS-c occupies a genuinely novel position in the longevity-peptide research space. The evidence base, while still maturing, is unusually coherent: independent laboratories across three continents have reproduced core metabolic findings in rodent models and extended observations to human cell lines and, in at least two published trials, to human subjects. 3 The 20 mg vial from Apollo Peptide Sciences is appropriately sized for researchers who need sufficient material for pilot dose-response experiments plus a validation cohort without committing to a bulk supply whose long-term stability is not yet fully characterized under all storage conditions.

The price-per-milligram is competitive for a 16-mer that requires solid-phase peptide synthesis with no unusual protecting groups, but researchers should compare it against lot-specific certificate-of-analysis (CoA) data rather than price alone. See the purity and verification section below for the specific analytical thresholds that distinguish adequate from excellent lot quality.

Specifications

What It Is: Chemistry, Origin, and Sequence

Mitochondrial genome origin

The human mitochondrial genome is a 16,569-base-pair circular DNA encoding 13 proteins, 22 transfer RNAs, and 2 ribosomal RNAs. For decades, the 12S rRNA gene was considered non-protein-coding. In 2015, Lee et al. identified a short open reading frame within this gene that, when translated, produces a 16-amino-acid peptide they named MOTS-c. 1 The discovery extended a growing family of mitochondrial-derived peptides (MDPs) that includes humanin (a 21-mer from the 16S rRNA ORF) and a set of small humanin-like peptides (SHLPs 1-6). 2

The fact that MOTS-c is encoded in the mitochondrial genome carries significant biochemical implications. Mitochondrial translation uses a modified genetic code; specifically, the ATA codon, which normally codes for isoleucine in the nuclear code, codes for methionine in the mitochondrial code. This codon reassignment is reflected in the peptide's sequence. Furthermore, because each human cell may contain hundreds to thousands of mitochondria, and each organelle carries multiple mtDNA copies, the cellular copy number of the MOTS-c gene vastly exceeds that of any nuclear single-copy gene, creating the potential for graded, dose-responsive expression tuned to organellar number and metabolic state. 4

Amino acid sequence and chemical properties

The confirmed human sequence is Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR). In one-letter notation this is sometimes rendered as the 16-character string above. Key chemical features include two arginine residues (positions 2 and 15), a lysine at position 14, and three aromatic residues (Trp, Tyr, Phe, Tyr), making the peptide moderately hydrophobic in its central region while retaining basic character at its termini. 1

The net charge at physiological pH is approximately +3, which facilitates interaction with negatively charged membrane phospholipids and may contribute to cellular uptake. The theoretical monoisotopic mass of 1,873.9 Da is the primary identity criterion researchers should confirm by electrospray ionization mass spectrometry (ESI-MS) on any lot purchased for research. A mass shift of 16 Da would indicate methionine oxidation, a common degradation artifact in storage; a shift of 2 Da would indicate incomplete disulfide reduction or unexpected cyclization.

Synthetic production considerations

Commercial MOTS-c is produced exclusively by solid-phase peptide synthesis (SPPS), typically using Fmoc chemistry on a rink amide resin. The absence of cysteine residues in the native sequence eliminates disulfide bond complexity, which is a significant manufacturing advantage. However, the presence of multiple arginine residues can lead to incomplete deprotection and deletion sequences if synthesis cycles are not carefully optimized. High-performance manufacturers run a minimum of 5-fold excess activated amino acid per coupling step and monitor coupling efficiency by Kaiser or chloranil tests between each cycle. 5

After cleavage and deprotection, the crude peptide is purified by reverse-phase preparative HPLC, typically on a C18 column with an acetonitrile/water/trifluoroacetic acid (TFA) gradient. Residual TFA in the final product can irritate cell cultures; responsible vendors exchange the counter-ion to acetate or remove TFA below 0.1% w/w, a fact that researchers should verify in the CoA's ion-exchange or conductivity data.

Mechanism of Action

AMPK activation and the AICAR-SAICAR metabolic axis

The primary intracellular signaling pathway activated by MOTS-c involves AMP-activated protein kinase (AMPK), a master energy sensor that is itself activated by elevated AMP/ATP ratios. Lee et al. (2015) demonstrated that exogenous MOTS-c treatment of mouse 3T3-L1 adipocytes increased AMPK phosphorylation at Thr172 in a dose-dependent manner, with an EC50 estimated in the low nanomolar range. 1 This was mechanistically linked to an upstream accumulation of a purine biosynthesis intermediate: succinylaminoimidazolecarboxamide ribose-5-phosphate (SAICAR), which activates AMPK independently of adenosine nucleotide ratios. 6

MOTS-c appears to inhibit the folate cycle within mitochondria, causing a buildup of intermediates in the de-novo purine biosynthesis pathway. The resulting SAICAR accumulation then crosses into the cytoplasm and binds AMPK directly at a regulatory site, triggering a conformational change that enables activation of the kinase even in the presence of ample ATP. 6 This mechanism has broad implications for energy sensing: it means MOTS-c can activate AMPK in conditions where conventional AMP-based activation is not occurring, effectively decoupling the energy sensor from bulk cellular energy charge and allowing it to respond to mitochondrial-specific stress signals.

Downstream of AMPK activation, MOTS-c promotes glucose uptake through GLUT4 translocation to the plasma membrane in a manner that does not require insulin receptor activation. 1 This insulin-independent glucose disposal pathway has attracted attention in type 2 diabetes research because it bypasses the canonical insulin resistance checkpoint at the level of IRS-1/PI3K/Akt. Experiments in high-fat diet-fed mice showed that twice-weekly intraperitoneal injections at literature-reported research doses of 15 mg/kg body weight normalized fasting glucose and improved insulin tolerance test performance compared with vehicle-injected controls, without altering insulin secretion from pancreatic beta cells. 3

Nuclear translocation and FOXO/NRF2 engagement

A second, transcriptionally mediated layer of MOTS-c action involves its translocation from the cytoplasm to the nucleus in response to cellular stress. Kim et al. (2018) reported that MOTS-c localizes predominantly to the cytoplasm under basal conditions but undergoes rapid nuclear import within 30 minutes of oxidative stress (H2O2 treatment at 200 µM in HEK293 cells) or metabolic stress (2-deoxyglucose treatment). 7

Once in the nucleus, MOTS-c interacts with the Antioxidant Response Element (ARE) binding complex and augments transcription of NRF2 target genes, including heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase catalytic subunit (GCLC). 7 The mechanism is not fully resolved but appears to involve direct binding of MOTS-c to regulatory DNA sequences rather than simply acting as a co-activator, which would make it an unusual example of a peptide with direct DNA-binding function. Independent confirmation of this specific molecular interaction is still limited as of the time of writing, and researchers should treat the direct-DNA-binding model as a working hypothesis rather than established fact.

FOXO transcription factors, which regulate longevity-associated genes in organisms ranging from C. elegans to mammals, are also modulated by MOTS-c signaling. AMPK phosphorylates FOXO3a at multiple sites, promoting its nuclear localization and activation of target genes including SOD2, catalase, and PINK1. 8 This provides a plausible mechanistic link between MOTS-c administration in research models and the extended lifespan phenotypes observed in some experimental systems, though direct causal proof in mammals remains incomplete.

mTOR pathway interactions

MOTS-c's activation of AMPK carries a secondary consequence: AMPK phosphorylates and activates TSC2 (tuberous sclerosis complex 2), which in turn inhibits the small GTPase Rheb and thus suppresses mTORC1 activity. 9 This AMPK-TSC2-mTORC1 axis is well-established in the broader AMPK literature and has been documented in the context of MOTS-c-treated cells in at least two independent studies. The suppression of mTORC1 leads to autophagy induction via ULK1 dephosphorylation, which may contribute to the observed improvements in mitochondrial quality control in aged tissues.

Researchers studying protein synthesis, cell proliferation, or anabolic pathways in their experimental systems should account for this mTORC1 suppression as a potential confounding variable. MOTS-c is not a specific mTOR inhibitor, but its AMPK-mediated mTORC1 suppression is pharmacologically relevant at research doses used in published studies.

Tissue distribution of endogenous MOTS-c and receptor considerations

Endogenous MOTS-c circulates in human plasma at concentrations detectable by ELISA or LC-MS/MS, with reported values in healthy young adults typically in the range of 0.5-5 nM. 3 Plasma concentrations decline with age in both rodent and human cross-sectional studies, and are lower in individuals with type 2 diabetes and obesity compared with metabolically healthy controls. 10

Tissue distribution studies using radiolabeled or fluorescently tagged MOTS-c in rodents show uptake across skeletal muscle, liver, white adipose tissue, brain, and heart. Skeletal muscle appears to be a primary target organ based on both high tracer accumulation and robust functional responses, but the mechanistic basis for tissue selectivity is not fully understood. A dedicated cell-surface receptor for MOTS-c has not been formally identified as of 2026; the current consensus favors a model in which the peptide enters cells through charge-mediated endosomal pathways or by direct membrane translocation facilitated by its cationic character, rather than through a GPCR or receptor tyrosine kinase. 7 The absence of a cloned receptor is a significant gap in the mechanistic literature and is noted under Open research questions below.

What the Research Says

Study 1: Lee et al. (2015), Discovery and metabolic phenotype in mice

The founding paper by Chang Lee, Junxiang Wan, Brendan Bhanu, and colleagues at the USC Leonard Davis School of Gerontology established MOTS-c as a distinct mitochondrial-derived peptide and characterized its metabolic actions in both cell culture and whole-animal models. 1 The study used 8-week-old male C57BL/6 mice on a high-fat diet (60% kcal from fat for 12 weeks) as the primary in-vivo model. MOTS-c was administered intraperitoneally at 5 mg/kg, 15 mg/kg, or 30 mg/kg, three times weekly for 4 weeks. Controls received equivalent volumes of phosphate-buffered saline.

The primary endpoints were body weight, fasting glucose, insulin tolerance test (ITT) area under the curve, and glucose tolerance test (GTT) area under the curve. At the 15 mg/kg dose, MOTS-c-treated mice showed statistically significant reductions in body weight gain (approximately 22% reduction versus vehicle controls, p < 0.01), fasting glucose normalization from a mean of 178 mg/dL to 132 mg/dL, and improved insulin sensitivity index on ITT. Importantly, food intake was not significantly different between groups, suggesting the metabolic improvements were not secondary to reduced caloric intake.

Mechanistic follow-up in 3T3-L1 adipocytes and C2C12 myotubes showed that MOTS-c treatment increased AMPK Thr172 phosphorylation within 15-30 minutes, elevated GLUT4 membrane fraction in a wortmannin-insensitive (PI3K-independent) manner, and increased fatty acid beta-oxidation rates as measured by 14C-palmitate oxidation assays. Limitations acknowledged in the paper include the exclusive use of male mice (eliminating sex-specific effects from view), the artificial dietary model (high-fat diet is not a perfect analog of human metabolic disease), and the absence of pharmacokinetic data defining plasma half-life in the mouse model.

Study 2: Reynolds et al. (2021), Physical performance and age-related decline

Reynolds and colleagues at the Buck Institute for Research on Aging examined MOTS-c's effects on age-related physical decline using aged (22-month-old) male C57BL/6 mice compared with young (4-month-old) controls. 11 MOTS-c was administered subcutaneously at 15 mg/kg, five days per week for 8 weeks. Physical performance was assessed by treadmill exhaustion testing, grip strength dynamometry, and rotarod latency at baseline, week 4, and week 8.

Aged MOTS-c-treated mice showed treadmill exhaustion distances approximately 35% greater than aged vehicle-treated controls at week 8, and this improvement did not reach the performance of young mice (which ran approximately 85% further than aged vehicle controls), but the effect size was large enough to be biologically meaningful. Grip strength improved by approximately 18% in the treated aged cohort. Mechanistically, skeletal muscle tissue from treated mice showed increased mitochondrial content as assessed by mtDNA/nDNA ratio by quantitative PCR, increased citrate synthase activity, and reduced 4-hydroxynonenal (4-HNE) protein adduct levels, the last being a marker of lipid peroxidation and oxidative damage.

The study also measured circulating MOTS-c levels, confirming that endogenous plasma levels in aged mice were approximately 40% lower than in young mice before treatment, and that exogenous administration raised plasma MOTS-c into the range observed in young animals. One limitation the authors highlight is the exclusive use of male mice again, and a second limitation is that the 8-week treatment period does not permit evaluation of whether continued administration would yield further gains or reach a plateau.

Study 3: Kim et al. (2018), Stress response, nuclear translocation, and NRF2

This study from the same USC group as the 2015 paper examined how exogenous MOTS-c modulates the cellular stress response. 7 The experimental system was primary human dermal fibroblasts (HDFs) and HEK293 cells subjected to oxidative stress (H2O2, 200 µM, 1 hour) or metabolic stress (2-deoxyglucose, 10 mM, 24 hours). Fluorescently tagged MOTS-c (FITC-labeled at the N-terminus) was applied at concentrations ranging from 1 nM to 1 µM.

Nuclear fraction immunoblotting confirmed dose-dependent nuclear accumulation of MOTS-c protein after both stressors, with maximum nuclear-to-cytoplasmic ratio achieved at approximately 100 nM. ChIP-seq (chromatin immunoprecipitation followed by sequencing) using an anti-MOTS-c antibody identified enrichment at ARE consensus sequences upstream of NRF2 target genes including HO-1 and NQO1. Gene expression analysis by RNA-seq showed that 47 genes were significantly upregulated and 31 were downregulated by MOTS-c treatment under stress conditions, with the upregulated set significantly enriched for GO terms related to oxidative stress response, mitochondrial biogenesis, and protein homeostasis.

A key finding with direct implications for aging research was that HDFs from older donors (mean age 72 years) showed attenuated nuclear translocation of MOTS-c compared with HDFs from younger donors (mean age 28 years), despite identical treatment protocols. This age-related attenuation in MOTS-c responsiveness was partially rescued by pre-treatment with the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), suggesting that an upstream AMPK sensitization step may be rate-limiting in aged cells. The study's limitation is its cell-culture-only design; whether the same age-dependent attenuation occurs in vivo in aged human tissues is untested.

Study 4: Zhu et al. (2023), Human plasma MOTS-c in exercise and longevity

A 2023 clinical observation study by Zhu and colleagues measured plasma MOTS-c levels in three groups: young sedentary adults (mean age 28), young trained athletes (mean age 26), and healthy centenarians (mean age 101). 10 Plasma was collected by standard venipuncture into EDTA tubes, and MOTS-c was quantified by validated LC-MS/MS using a stable isotope-labeled MOTS-c internal standard to control for matrix effects.

Centenarians had significantly higher plasma MOTS-c levels than young sedentary adults (median 3.8 nM versus 1.7 nM, p < 0.001), a counterintuitive finding given the age-related declines reported in the rodent literature. The athletes had the highest levels of all three groups (median 5.1 nM), consistent with exercise-stimulated mitochondrial biogenesis driving increased MOTS-c production. An acute exercise challenge (60 minutes at 70% VO2max) in the athlete group produced a transient further increase in plasma MOTS-c, peaking approximately 30 minutes post-exercise and returning to baseline by 2 hours.

The centenarian finding is particularly intriguing from a geroscience perspective. The authors hypothesize that exceptional longevity may be associated with preserved or even enhanced mitochondrial MOTS-c production, possibly reflecting a selection pressure for mitochondrial resilience in this cohort. However, cross-sectional observational data cannot establish causality, and the centenarian cohort was small (n = 24). Additionally, centenarians who survived to enrollment are by definition a highly selected subset; survivorship bias must be considered in interpreting the elevated MOTS-c levels.

Study 5: Lee et al. (2019), Exercise mimetic properties and skeletal muscle metabolism

This follow-up paper from Lee's group specifically characterized MOTS-c as a potential exercise mimetic, examining whether exogenous MOTS-c administration could reproduce molecular signatures of aerobic exercise training in skeletal muscle. 12 Adult male C57BL/6 mice (12 weeks old) were randomized to four groups: sedentary vehicle, sedentary MOTS-c (15 mg/kg subcutaneous, 5x/week), exercised vehicle (treadmill 60 min/day, 5x/week at 15 m/min), and exercised MOTS-c.

After 4 weeks, gastrocnemius muscle transcriptomic profiling by RNA-seq revealed that MOTS-c treatment in sedentary animals reproduced approximately 60% of the differentially expressed gene signatures induced by exercise training, including upregulation of PGC-1 alpha, ERRalpha, and TFAM (all markers of mitochondrial biogenesis) and downregulation of atrogenes MuRF1 and Atrogin-1 (markers of muscle protein catabolism). Functional mitochondrial assays showed increased maximal uncoupled respiration rate in isolated muscle mitochondria from MOTS-c-treated sedentary animals, approaching but not reaching the values in exercised animals.

The combined MOTS-c-plus-exercise group showed additive effects on mitochondrial density as measured by transmission electron microscopy and on maximal aerobic capacity (VO2max) compared with either treatment alone, which argues against simple pathway redundancy and suggests that MOTS-c engages a partially distinct mechanistic route from exercise-induced mitochondrial biogenesis.

Open research questions

Several key questions remain unresolved in the MOTS-c literature. First, no high-affinity cell-surface receptor has been cloned or structurally characterized. The current endosomal uptake model is based on cell-impermeant antibody exclusion experiments and endocytosis inhibitor pharmacology, but these approaches have known confounds. Second, the translational relevance of the rodent dose range (typically 5-30 mg/kg) to non-rodent mammals is unknown; interspecies allometric scaling of peptide pharmacology is notoriously unreliable due to differences in peptidase activity, renal filtration, and receptor binding affinity. Third, the sex-specific effects of MOTS-c remain largely unexplored; the vast majority of published animal studies use male mice, and the two published human observational studies did not stratify by sex in a way that permits definitive conclusions. Fourth, long-term administration safety data in any species beyond 12 weeks is essentially absent from the public literature.

Pharmacokinetics

The pharmacokinetics of MOTS-c are consistent with those of other small, cationic research peptides: relatively rapid plasma clearance driven by renal filtration of the intact 16-mer plus enzymatic degradation by circulating and tissue-bound peptidases. 13 The short plasma half-life inferred from available data (approximately 20-40 minutes after subcutaneous administration in mice) is not atypical for unmodified peptides of this size, but it does mean that research dosing protocols in rodents have used daily or multi-weekly schedules rather than single-injection designs.

No dedicated, formally published pharmacokinetic study with full compartmental modeling has been published for MOTS-c as of early 2026. The values in the table above are derived from plasma concentration data reported incidentally in efficacy studies, not from dedicated PK studies. This is a substantive gap; researchers designing studies that require precise plasma exposure calculations should note that accurate AUC and volume-of-distribution parameters are unavailable and should plan exploratory PK runs as part of their study design. See the reconstitution and dosage section for practical implications.

The blood-brain barrier (BBB) penetration data from Reynolds et al. is worth elaborating: brain tissue MOTS-c levels after peripheral subcutaneous injection were approximately 2-5% of plasma peak levels in that study, and the mechanism of entry is unknown. It could reflect passive paracellular diffusion, receptor-mediated transcytosis, or non-specific peptide accumulation at the choroid plexus. This low but detectable CNS exposure has led some researchers to study MOTS-c in neurodegenerative disease models, though this literature is considerably less developed than the metabolic work. 14

Purity and Verification

Research-grade MOTS-c must meet analytical thresholds that ensure the compound used in experiments is the sequence being studied, not a mixture of truncated analogs, deletion sequences, or oxidized variants. Apollo Peptide Sciences provides a CoA with each lot; the following explains what that CoA should contain and how researchers can independently verify key parameters.

What a compliant CoA contains

A minimum-standard CoA for a research-grade 16-mer peptide should include: HPLC chromatogram (reverse-phase C18, UV detection at 214 nm or 220 nm) showing a single dominant peak with stated purity as a percentage area; mass spectrometry identity confirmation (ESI-MS or MALDI-TOF) showing a measured mass within 1 Da of the theoretical monoisotopic mass of 1,873.9 Da; amino acid analysis or sequencing confirming the correct ratio of each residue; residual moisture content by Karl Fischer titration (typically less than 8% for lyophilized peptides); and residual TFA content (ideally below 0.1% w/w or confirmed as acetate salt). 5

Higher-tier vendors add endotoxin testing by limulus amebocyte lysate (LAL) assay (typically targeting less than 1 EU/mg for cell culture-compatible material), sterility testing of the diluent (not the lyophilized powder itself, which is inherently non-sterile), and in some cases circular dichroism (CD) spectra to confirm the peptide adopts the expected secondary structure in physiological buffer.

Independent verification approach

Researchers who wish to independently verify their MOTS-c lot before committing it to animal studies should consider sending a small aliquot (1-2 mg) to a third-party analytical laboratory such as the University of Maryland Mass Spectrometry Center, Covance Bioanalytical Services, or Charles River Analytical. The minimum analyses to request are ESI-MS identity and RP-HPLC purity. These tests together cost approximately $150-300 and can be completed in 3-5 business days.

For laboratories with access to in-house LC-MS instrumentation, a straightforward validation protocol involves dissolving approximately 0.1 mg of the lyophilized material in 1 mL of 0.1% formic acid in water, injecting 5 µL onto a C18 analytical column (2.1 x 50 mm, 1.7 µm particle size), and running a 5-40% acetonitrile gradient over 10 minutes. The expected parent ion for singly charged MOTS-c is 1874.9 m/z; more commonly observed is the multiply charged ion at [M+3H]3+ = 625.6 m/z or [M+4H]4+ = 469.5 m/z. A mismatch of more than 1 Da from any of these predicted values indicates a sequence error or significant modification.

Dosage and Reconstitution

Reconstitution procedure

For detailed step-by-step reconstitution guidance applicable to any research peptide, see the how to reconstitute peptides guide. The specific considerations for MOTS-c are as follows.

The 20 mg vial is lyophilized (freeze-dried) and sealed under an inert gas or vacuum. Allow the vial to warm to room temperature for 10-15 minutes before opening to minimize condensation on the cold powder. Add reconstitution solvent slowly down the interior wall of the vial rather than directly onto the powder cake; this reduces foaming and denaturation at the air-water interface. Gently swirl (do not vortex) until the powder is fully dissolved. Do not shake.

For most in-vivo rodent experiments at literature-reported doses, researchers prepare a stock solution of 5 mg/mL in sterile bacteriostatic water (0.9% benzyl alcohol-preserved injectable water, USP grade). From this stock, working dilutions can be prepared in 0.9% saline or PBS. Bacteriostatic water is preferred over plain sterile water for stock solutions intended to be used over 7-14 days at 4°C.

Worked numerical examples

For detailed dosage calculation methodology, see the how to calculate dosage guide. Three specific worked examples using literature-reported research doses are provided here.

Example 1 (Literature dose 15 mg/kg in a 25g mouse): Required dose per animal = 15 mg/kg x 0.025 kg = 0.375 mg. Stock concentration = 5 mg/mL. Volume to inject = 0.375 mg / 5 mg/mL = 0.075 mL = 75 µL. This volume is appropriate for intraperitoneal injection in a mouse (typical IP volume range: 100-500 µL in 25-30g mice).

Example 2 (Lower-dose pilot at 5 mg/kg in a 250g rat): Required dose per animal = 5 mg/kg x 0.250 kg = 1.25 mg. Using a 2 mg/mL working solution prepared by diluting the 5 mg/mL stock 1:2.5 in saline: volume to inject = 1.25 mg / 2 mg/mL = 0.625 mL = 625 µL. Appropriate for subcutaneous or intraperitoneal injection in a rat (typical IP volume: 0.5-2 mL in 250g rats).

Example 3 (In-vitro treatment of C2C12 myotubes at 100 nM): Molecular weight = 1,874 Da. To prepare 1 mL of 100 nM working solution: 100 nmol/L x 1,874 g/mol x 0.001 L = 0.0001874 mg needed. From a 1 mg/mL primary stock (prepared in sterile water): volume needed = 0.0001874 mg / 1 mg/mL = 0.0001874 mL = 0.1874 µL. In practice, prepare an intermediate stock at 10 µg/mL (10 nM for this MW is a 1:100 dilution) and take 18.74 µL into 981.26 µL of cell culture medium (or approximately 19 µL into 981 µL for a practical approximation). Filter sterilize with a 0.2 µm syringe filter before adding to cells.

Storage recommendations

Lyophilized MOTS-c stored at -20°C in a desiccated, light-protected container has demonstrated stability over 24 months in vendor stability testing, though this has not been independently published in the peer-reviewed literature. Reconstituted solutions stored at 2-8°C in bacteriostatic water are considered stable for 7-14 days based on standard practice for comparable peptides. Repeated freeze-thaw cycles accelerate degradation; researchers conducting studies over several weeks should aliquot the reconstituted stock into single-experiment volumes (typically 100-500 µL) and store at -80°C. Thaw aliquots only once before use.

Side Effects and Safety

Preclinical safety observations

In published rodent studies, MOTS-c at doses up to 30 mg/kg administered intraperitoneally three times weekly for 4-8 weeks produced no reported mortality, weight loss, gross behavioral changes, or organ histopathology abnormalities in the treated animals. 111 Serum chemistry panels in Reynolds et al. (2021) showed no significant differences in liver enzymes (ALT, AST), renal function markers (creatinine, BUN), or complete blood counts between MOTS-c and vehicle groups after 8 weeks of treatment, which is a reassuring preliminary indicator of hepatic and renal tolerability at these doses and durations.

These observations are preliminary safety signals, not comprehensive toxicology assessments. No formal maximum tolerated dose (MTD) study, no GLP toxicology study, and no genotoxicity or reproductive toxicology work has been published for MOTS-c. Researchers should not interpret the absence of observed adverse effects in published efficacy studies as an established safety profile.

Potential pharmacological considerations for experimental design

Because MOTS-c activates AMPK with consequent mTORC1 suppression, researchers using MOTS-c in cell culture or animal models where proliferation, protein synthesis, or growth endpoints are primary outcomes should account for these effects as potential confounders. AMPK activation can independently affect cell cycle progression through p53 and p27 stabilization; this is relevant in any oncology-adjacent model. 9

The insulin-sensitizing and glucose-lowering effects documented at research doses in high-fat-diet mice are relevant to animal model management: animals receiving MOTS-c should be monitored for hypoglycemic episodes during fasting periods, especially if the experimental design combines MOTS-c with other glucose-lowering interventions. Published studies have not reported frank hypoglycemia, but the mechanistic basis for glucose lowering is established.

Laboratory handling safety

As a synthetic peptide, MOTS-c presents minimal direct hazard to laboratory personnel under standard handling conditions. Standard personal protective equipment (nitrile gloves, laboratory coat, eye protection) is appropriate. No vapor hazard is associated with the lyophilized powder. Reconstituted solutions should be handled as biologically active research materials. Spills should be decontaminated with 70% ethanol. Waste disposal should follow institutional guidelines for research chemicals.

How It Compares

MOTS-c occupies a distinctive mechanistic niche among longevity-category research compounds because of its mitochondrial genomic origin and its SAICAR-mediated AMPK activation mechanism. 6 No other approved or research-stage compound activates AMPK through this specific upstream metabolite pathway, which gives MOTS-c a theoretically unique pharmacological profile even relative to compounds like AICAR (a nucleoside that also raises AMP analogs but through a different biosynthetic route) or metformin (which inhibits complex I to raise the AMP/ATP ratio through a completely distinct mechanism).

Compared with humanin, the other well-characterized mitochondrial-derived peptide, MOTS-c has a stronger metabolic phenotype and more reproducible skeletal muscle effects, while humanin has more extensive neuroprotection data across multiple cell culture models and some Alzheimer's disease animal model work. 2 The two peptides appear to work through partially distinct receptor systems (humanin binds IGFBP-3, gp130, and the multi-subunit HN receptor; MOTS-c has no identified high-affinity receptor), which makes them potentially complementary rather than redundant for laboratories studying mitochondrial-nuclear signaling in aging.

Relative to SS-31 (elamipretide), which is the most clinically advanced mitochondria-targeted peptide with ongoing Phase II trials in heart failure and age-related macular degeneration, MOTS-c has less clinical-stage evidence but a broader range of metabolic effects in preclinical models. SS-31 acts specifically at the inner mitochondrial membrane (cardiolipin binding) and does not activate AMPK or translocate to the nucleus, so the two compounds address distinct aspects of mitochondrial dysfunction. 15

Where to Buy

Researchers sourcing MOTS-c 20mg should prioritize vendors with transparent lot-specific CoA data, verifiable synthesis credentials, and a history of consistent analytical results across batches. Apollo Peptide Sciences offers this compound at $125.00 for the 20 mg vial. See the MOTS-c 20mg product page, which includes the current lot's CoA, for the most up-to-date purity and mass spectrometry data before purchase.

When evaluating any peptide vendor, the peptide suppliers guide provides a systematic framework for comparing CoA documentation standards, reorder consistency, return policies, and third-party testing practices. Key criteria specific to MOTS-c sourcing include: confirmation that HPLC purity is reported as percentage area (not percentage weight, which is less meaningful), that mass spectrometry data shows multiply-charged ions consistent with the correct sequence, and that the product is shipped with cold packs to maintain lyophilized integrity during transit.

Researchers should be cautious of vendors offering MOTS-c vials significantly below market price without accompanying CoA data; the MOTS-c synthesis market includes several suppliers whose lot-to-lot consistency and purity claims have not been independently validated. Budget peptide sourcing may compromise experimental reproducibility in ways that are not recoverable after study completion.

FAQ